Skip to main content
Journal cover image

The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing.

Publication ,  Journal Article
Ryan, S; Visgauss, J; Kerr, D; Helmkamp, J; Said, N; Vinson, E; O'Donnell, P; Li, X; Jung, S-H; Cardona, D; Eward, W; Brigman, B
Published in: Sarcoma
2018

INTRODUCTION: Extremity lipomas and well-differentiated liposarcomas (WDLs) are difficult to distinguish on MR imaging. We sought to evaluate the accuracy of MRI interpretation using MDM2 amplification, via fluorescence in-situ hybridization (FISH), as the gold standard for pathologic diagnosis. Furthermore, we aimed to investigate the utility of a diagnostic formula proposed in the literature. METHODS: We retrospectively collected 49 patients with lipomas or WDLs utilizing MDM2 for pathologic diagnosis. Four expert readers interpreted each patient's MRI independently and provided a diagnosis. Additionally, a formula based on imaging characteristics (i.e. tumor depth, diameter, presence of septa, and internal cystic change) was used to predict the pathologic diagnosis. The accuracy and reliability of imaging-based diagnoses were then analyzed in comparison to the MDM2 pathologic diagnoses. RESULTS: The accuracy of MRI readers was 73.5% (95% CI 61-86%) with substantial interobserver agreement (κ=0.7022). The formula had an accuracy of 71%, which was not significantly different from the readers (p=0.71). The formula and expert observers had similar sensitivity (83% versus 83%) and specificity (64.5% versus 67.7%; p=0.659) for detecting WDLs. CONCLUSION: The accuracy of both our readers and the formula suggests that MRI remains unreliable for distinguishing between lipoma and WDLs.

Duke Scholars

Published In

Sarcoma

DOI

ISSN

1357-714X

Publication Date

2018

Volume

2018

Start / End Page

1901896

Location

Egypt

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3203 Dentistry
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ryan, S., Visgauss, J., Kerr, D., Helmkamp, J., Said, N., Vinson, E., … Brigman, B. (2018). The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing. Sarcoma, 2018, 1901896. https://doi.org/10.1155/2018/1901896
Ryan, Sean, Julia Visgauss, David Kerr, Joshua Helmkamp, Nicholas Said, Emily Vinson, Patrick O’Donnell, et al. “The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing.Sarcoma 2018 (2018): 1901896. https://doi.org/10.1155/2018/1901896.
Ryan S, Visgauss J, Kerr D, Helmkamp J, Said N, Vinson E, et al. The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing. Sarcoma. 2018;2018:1901896.
Ryan, Sean, et al. “The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing.Sarcoma, vol. 2018, 2018, p. 1901896. Pubmed, doi:10.1155/2018/1901896.
Ryan S, Visgauss J, Kerr D, Helmkamp J, Said N, Vinson E, O’Donnell P, Li X, Jung S-H, Cardona D, Eward W, Brigman B. The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing. Sarcoma. 2018;2018:1901896.
Journal cover image

Published In

Sarcoma

DOI

ISSN

1357-714X

Publication Date

2018

Volume

2018

Start / End Page

1901896

Location

Egypt

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3203 Dentistry
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences